Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABBDABF 47 Days Payable is 41.17 as of Mar. 2026, which is 0% below its 10-year median of 41.31. GuruFocus rates BDABF with a GF Score™ of 47/100 and a GF Value™ of $14.73. The stock has 2 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 75.75% on this metric.
The historical rank and industry rank for Boule Diagnostics AB's Days Payable or its related term are showing as below:
BDABF'
s Days Payable Range Over the Past 10 Years
Min: 35.43 Med: 41.31 Max: 48.62
Current: 39.84
During the past 13 years, Boule Diagnostics AB's highest Days Payable was 48.62. The lowest was 35.43. And the median was 41.31.
BDABF's Days Payable is ranked worse than 75.75% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs BDABF: 39.84
Boule Diagnostics AB's Days Payable
declined
from Mar. 2025 (51.96) to Mar. 2026 (41.17).
It may suggest that Boule Diagnostics ABaccelerated paying its suppliers.
Boule Diagnostics AB Days Payable Related Terms
Boule Diagnostics AB Days Payable Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boule Diagnostics AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Boule Diagnostics AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (BDABF) has a Days Payable of 41.17 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Boule Diagnostics AB and its competitors. This is near median its historical median of 41.31. Over the past decade, Boule Diagnostics AB's Days Payable has ranged from 35.43 to 48.62. According to the industry distribution chart, Boule Diagnostics AB ranks #603 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 75.8%.
Is Boule Diagnostics AB's Days Payable too high?
Boule Diagnostics AB's current Days Payable of 41.17 is near median its 10-year median of 41.31. Over the past 10 years, this metric has ranged from a low of 35.43 to a high of 48.62. The Medical Devices & Instruments industry median Days Payable is 67.97. Boule Diagnostics AB's value of 41.17 is 39.4% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #603 out of 796 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #603 out of 796 companies for Days Payable. This places Boule Diagnostics AB in the lower half of its industry. The industry median Days Payable is 67.97. Boule Diagnostics AB's value of 41.17 is 39.4% below this benchmark. Historically, Boule Diagnostics AB's own Days Payable has ranged from 35.43 to 48.62 over the past decade. While the company's 10-year median is 41.31 vs. the industry median of 67.97, Boule Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Days Payable of 41.17 is 39.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Days Payable is 41.17, which is near median its own 10-year median of 41.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (BDABF) has a current Days Payable of 41.17. The stock's GF Value™ is $14.73, compared to a current price of $7.84 — trading 46.8% below its estimated fair value. The current Days Payable is 41.17, which is near median its 10-year median of 41.31 and 39.4% below the Medical Devices & Instruments industry median of 67.97. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Boule Diagnostics AB (BDABF), the current Days Payable is 41.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (BDABF) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of $7.84 is trading 46.8% below its estimated GF Value™ of $14.73.
Key valuation signals for BDABF:
Days Payable: 41.17 (near median its 10-year median of 41.31)
GF Value™: $14.73 vs. price of $7.84 (46.8% below fair value)
Industry Position: 39.4% below the Medical Devices & Instruments median (#603 of 796)
No single metric tells the full story. See the BDABF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for BDABF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDABF has been successfully added to your 
